<DOC>
	<DOCNO>NCT00594347</DOCNO>
	<brief_summary>The present study intend investigate use booster dose sanofi pasteur 's Pneumo 23 vaccine second year life follow 3-dose prim Wyeth 's Prevnar vaccine . The researcher use cohort subject receive 3 dos Prevnar® 2 , 4 , 6 month age context clinical study A3L12 Hexavalent combine vaccine ( DTaP-IPV-HB-PRP~T )</brief_summary>
	<brief_title>Immunogenicity Safety Booster Dose Pneumo 23® 12 18 Months-Old Children Primed With Prevnar</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Aged 12 18 month day inclusion Informed consent form sign parent/legally acceptable representative independent witness request local Ethics Committee regulation or/and parent/legally acceptable representative illiterate Child complete threedose primary vaccination Prevnar® hexavalent combine vaccine study ( study A3L12 ) . Subjects parent/guardian able attend schedule visit comply study procedure Participation another clinical study investigate vaccine , drug , medical device , medical procedure 4 week precede study vaccination Planned participation another clinical study present study period Known suspect congenital acquire immunodeficiency , immunosuppressive therapy longterm systemic corticosteroid therapy Known systemic hypersensitivity vaccine component history lifethreatening reaction study vaccine vaccine contain substance Chronic illness stage could interfere study conduct completion , opinion investigator Receipt blood bloodderived product since birth might interfere assessment immune response Receipt vaccine 4 week precede study vaccination Planned receipt vaccine 4 week precede follow study vaccination History seizures Known personal Human Immunodeficiency Virus ( HIV ) , Hepatitis B ( HB ) antigen Hepatitis C seropositivity History pneumococcal infection ( confirm either clinically , serologically microbiologically ) Previous booster vaccination pneumococcal disease either study vaccine ( ) another vaccine Thrombocytopenia , bleed disorder anticoagulant 3 week precede inclusion contraindicate IM vaccination Febrile illness ( temperature ≥ 38°C ) moderate severe acute illness/infection day vaccination , accord investigator judgment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Streptococcus pneumoniae</keyword>
</DOC>